• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

洗肠菌群移植联合生物制剂促进难治性重症溃疡性结肠炎合并复发性肠道感染的组织学缓解:一例报告

Washed microbiota transplantation combined with biological agents promotes histological remission in refractory severe ulcerative colitis with recurrent intestinal infection: A case report.

作者信息

Wu Qiong, Yang Liu-Si, Huang Hong-Li, Li Ying-Fei, Zhou Yong-Jian, Xu Hao-Ming

机构信息

Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.

Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.

出版信息

Arab J Gastroenterol. 2024 Nov;25(4):448-454. doi: 10.1016/j.ajg.2024.07.008. Epub 2024 Jul 29.

DOI:10.1016/j.ajg.2024.07.008
PMID:39079826
Abstract

Ulcerative colitis (UC) is a chronic non-specific colitis disease. In recent years, fecal microbiota transplantation (FMT), including improved washed microbiota transplantation (WMT), and biological agents have helped improve the prognosis of patients with UC. However, a significant number of patients with moderate to severe UC do not get relief from glucocorticoids, immunosuppressants, and TNF-α antagonists. Patients with severe UC are frequently burdened with opportunistic infections and subsequent surgical interventions. Combined treatment modalities are crucial for patients with severe UC and opportunistic infections. Herein, we reported a case of a 25-year-old female with refractory severe UC complicated with recurrent Clostridioides difficile infection and recurrent cytomegalovirus infection for six years. Surgical removal of the affected bowel segment was almost unavoidable. She showed endoscopic and histological recovery after comprehensive WMT and Vedolizumab treatment. The following are our learnings from the case: 1. A combination of WMT and biological agents can potentially obviate the necessity for surgical treatment in patients with refractory severe UC and promote histological remission. 2. Personalized comprehensive treatment and chronic disease management models for patients with UC should be emphasized. 3. WMT can help treat opportunistic infections, which may also strengthen the treatment with gut-targeted biological agents when traditional TNF-α antagonists show poor efficacy.

摘要

溃疡性结肠炎(UC)是一种慢性非特异性结肠疾病。近年来,粪便微生物群移植(FMT),包括改良的洗肠微生物群移植(WMT)和生物制剂,有助于改善UC患者的预后。然而,相当数量的中度至重度UC患者并未从糖皮质激素、免疫抑制剂和肿瘤坏死因子-α拮抗剂中获得缓解。重度UC患者经常面临机会性感染和随后的手术干预。联合治疗模式对重度UC和机会性感染患者至关重要。在此,我们报告了一例25岁女性难治性重度UC患者,该患者并发复发性艰难梭菌感染和复发性巨细胞病毒感染达六年之久。几乎不可避免地需要手术切除受影响的肠段。在接受全面的WMT和维多珠单抗治疗后,她的内镜和组织学表现均恢复正常。以下是我们从该病例中获得的经验教训:1. WMT和生物制剂联合使用可能避免难治性重度UC患者进行手术治疗的必要性,并促进组织学缓解。2. 应强调针对UC患者的个性化综合治疗和慢性病管理模式。3. WMT有助于治疗机会性感染,当传统的肿瘤坏死因子-α拮抗剂疗效不佳时,这也可能加强肠道靶向生物制剂的治疗效果。

相似文献

1
Washed microbiota transplantation combined with biological agents promotes histological remission in refractory severe ulcerative colitis with recurrent intestinal infection: A case report.洗肠菌群移植联合生物制剂促进难治性重症溃疡性结肠炎合并复发性肠道感染的组织学缓解:一例报告
Arab J Gastroenterol. 2024 Nov;25(4):448-454. doi: 10.1016/j.ajg.2024.07.008. Epub 2024 Jul 29.
2
Fecal transplantation for treatment of inflammatory bowel disease.粪便移植治疗炎症性肠病。
Cochrane Database Syst Rev. 2018 Nov 13;11(11):CD012774. doi: 10.1002/14651858.CD012774.pub2.
3
Case report: Fecal microbiota transplant for infection in a pregnant patient with acute severe ulcerative colitis.病例报告:粪便微生物群移植治疗一名患有急性重症溃疡性结肠炎的孕妇感染
Front Immunol. 2024 Nov 21;15:1417003. doi: 10.3389/fimmu.2024.1417003. eCollection 2024.
4
Refractory ulcerative colitis stabilized by interval washed microbiota transplantation: less is more.间隔冲洗菌群移植稳定难治性溃疡性结肠炎:少即是多。
Curr Med Res Opin. 2022 Apr;38(4):531-534. doi: 10.1080/03007995.2022.2030563. Epub 2022 Feb 1.
5
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.复发性艰难梭菌感染和/或溃疡性结肠炎患者单次供体粪便微生物群移植的纵向微生物组分析
PLoS One. 2018 Jan 31;13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018.
6
Older patients benefit more from sequential courses of washed microbiota transplantation than younger population with ulcerative colitis.与年轻的溃疡性结肠炎患者相比,老年患者从序贯疗程的经洗涤微生物群移植中获益更多。
Scand J Gastroenterol. 2023 Jul-Dec;58(8):890-899. doi: 10.1080/00365521.2023.2185476. Epub 2023 Mar 2.
7
Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis.粪菌移植改变肠道菌群失调并不能诱导慢性活动性溃疡性结肠炎患者缓解。
Inflamm Bowel Dis. 2013 Sep;19(10):2155-65. doi: 10.1097/MIB.0b013e31829ea325.
8
Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis.粪便微生物群移植治疗同时患有溃疡性结肠炎的复发性艰难梭菌感染患者。
J Autoimmun. 2023 Dec;141:103033. doi: 10.1016/j.jaut.2023.103033. Epub 2023 Apr 19.
9
Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: a case series.粪便微生物移植治疗后中重度溃疡性结肠炎复发及再次 FMT 的疗效:病例系列研究。
BMC Gastroenterol. 2020 Nov 26;20(1):401. doi: 10.1186/s12876-020-01548-w.
10
Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study.单一致病菌移植治疗复发性活动期溃疡性结肠炎的长期疗效和安全性:一项前瞻性随机试验研究。
Microb Cell Fact. 2021 Jan 19;20(1):18. doi: 10.1186/s12934-021-01513-6.

引用本文的文献

1
Clinical effects of endoscopic resection of hypertrophied anal papillae combined with internal hemorrhoid ligation therapy: a retrospective study.内镜下肥大肛乳头切除术联合内痔结扎术的临床疗效:一项回顾性研究
Surg Endosc. 2025 Apr;39(4):2250-2255. doi: 10.1007/s00464-025-11601-y. Epub 2025 Feb 11.